ERBB2 and breast carcinoma: Growing evidence focused on immunotherapy for breast cancer has demonstrated that higher numbers of TILs and Treg cells are significantly associated with the TNBC and HER2 overexpression subtypes (31, 32), and more PD-1+ TILs have been found in TNBC and were correlated with higher immune scores (33).